432 related articles for article (PubMed ID: 28185797)
21. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
22. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
Madanat Y; Sekeres MA
Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
[TBL] [Abstract][Full Text] [Related]
23. Optimizing hypomethylating agents in myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
[TBL] [Abstract][Full Text] [Related]
24. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
[TBL] [Abstract][Full Text] [Related]
25. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
Chandhok NS; Lewis R; Prebet T
Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
[TBL] [Abstract][Full Text] [Related]
26. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S56-9. PubMed ID: 26297279
[TBL] [Abstract][Full Text] [Related]
29. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
[TBL] [Abstract][Full Text] [Related]
30. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
31. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
32. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
34. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Borthakur G; Ahdab SE; Ravandi F; Faderl S; Ferrajoli A; Newman B; Issa JP; Kantarjian H
Leuk Lymphoma; 2008 Apr; 49(4):690-5. PubMed ID: 18398735
[TBL] [Abstract][Full Text] [Related]
35. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
36. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
37. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
38. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
Komrokji RS
Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
[TBL] [Abstract][Full Text] [Related]
39. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latremouille-Viau D; Shi S; Guerin A; Wu EQ; Sadek I; Cao X
Leuk Lymphoma; 2021 Jun; 62(6):1411-1421. PubMed ID: 33430673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
